![Jim Fenton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jim Fenton
Investor Relations Contact chez Association for Accessible Medicines
Profil
Jim Fenton is currently the Senior Vice President-Government Affairs at the Association for Accessible Medicines.
He completed his undergraduate degree at the University of Oregon and another undergraduate degree at Georgetown University.
Postes actifs de Jim Fenton
Sociétés | Poste | Début |
---|---|---|
Association for Accessible Medicines
![]() Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Investor Relations Contact | - |
Formation de Jim Fenton
Georgetown University | Undergraduate Degree |
University of Oregon | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Association for Accessible Medicines
![]() Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Commercial Services |